CalciMedica corrects private placement terms; raises up to ~$55M for clinical trials

CalciMedica, Inc.

Corrected offering: 4,985,610 shares, 306,506 pre-funded warrants, 5,292,116 common warrants at $3.827/unit.
Upfront gross proceeds $20.4M; potential $33.1M from warrant exercise for total ~$54M (press release: ~$55M).
Preliminary cash Dec 31, 2023: $11.2M; net proceeds to fund Phase 2 trials of Auxora in AP and AKI.
New investors include Deerfield affiliate, Soleus Capital, Stonepine, Aisling; existing Sanderling and Bering participated.
Tranche A warrants ($5.36) expire Dec 31, 2024 or 30 days after AP topline; Tranche B ($7.15) expire Dec 31, 2026 or after AKI topline.

item 1.01 item 2.02 item 3.02 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.98

CalciMedica, Inc. entered into Securities Purchase Agreement with certain accredited investors valued at $20.4 million (effective 2024-01-19).

Action: entry
Agreement: equity purchase
Counterparty: certain accredited investors
Value: $20.4 million
Effective: 2024-01-19

Exact text from the filing

On January 19, 2024, the Company and certain accredited investors (each an “Investor” and collectively, the “Investors”) entered into a securities purchase agreement (the “Securities Purchase Agreement”)

View on SEC.gov

623 material agreements filed in the last 30 days. Browse all material agreements →

CalciMedica, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-013513

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.